|
|
|
| The value of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor in breast cancer receiving adjuvant chemotherapy |
| HUANG Miao1 TIAN Wuguo2 HAO Shuai2 |
1.Nursing School， Chongqing Medical University， Chongqing 400016, China;
2.Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China |
|
|
|
Abstract Objective To investigate the value of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing chemotherapy-induced neutropenia in breast cancer and the influence on quality of life. Methods A total of 160 patients with breast cancer treated in Daping Hospital, Army Medical University from January 2018 and June 2019 were selected as study odjects. According to the random number method, they were divided into the experimental group (80 cases) and the control group (80 cases). All patients received a six cycle TEC chemotherapy programme, on this basis, the experimental group was prophylactic use of PEG-rhG-CS, while the control group was prophylactic use of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The efficacy and safety of the two groups were compared. The quality of life scale (FACT-B) was compared between the two groups. Results The incidence of febrile neutropenia between the two groups was not statistically significant (P > 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). After chemotherapy, physiological status, social/family status, emotional status, functional status, additional attention status and total score of the experimental group were all higher than those of the control group, with statistically significant differences (all P < 0.05). Conclusion Prophylactic use of PEG-rhG-CSF can effectively prevent the occurrence of neutropenia and FN in breast cancer chemotherapy, and is more conducive to maintaining a higher quality of life.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[2] Sledge GW，Mamounas EP，Hortobagyi GN，et al. Past，present，and future challenges in breast cancer treatment [J]. J Clin Oncol，2014，32（19）：1979-1986.
[3] De Santis C，Ma J，Bryan L，et al. Breast cancer statistics，2013 [J]. CA Cancer J Clin，2014，64（1）：52-62.
[4] Xie J，Cao J，Wang JF，et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy：an open-label，randomized，multicenter phase Ⅲ study [J]. Breast Cancer Res Treat，2018，168（2）：389-399.
[5] 江泽飞，许凤锐，樊菁，等.聚乙二醇化重组人粒细胞刺激因子预防乳腺癌患者化疗后中性粒细胞减少的多中心随机对照Ⅳ期临床观察[J].中华医学杂志，2018，98（16）：1231-1235.
[6] Yoo HJ，Ahn SH，Eremenco S，et al. Korean translation and validation of the functional assessment of cancer therapy-breast（FACT-B）scale version 4 [J]. Qual Life Res，2005，14（6）：1627-1632.
[7] 万崇华，张冬梅，汤学良，等.乳腺癌患者生命质量测定量表FACT-B中文版介绍[J].中国肿瘤，2002，11（6）：318-320.
[8] Goetz MP，Gradishar WJ，Anderson BO，et al. NCCN Guidelines insights：breast cancer，Version 3.2018 [J]. J Natl Compr Canc Netw，2019，17（2）：118-126.
[9] 马军，朱军，徐兵河，等.聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）临床应用中国专家共识[J].中国肿瘤临床，2016，43（7）：271-274.
[10] 中国临床肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J].中华肿瘤杂志，2017，39（11）：868-878.
[11] Crawford J，Becker PS，Armitage JO，et al. Myeloid Growth Factors，Version 2.2017，NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw，2017，15（12）：1520-1541.
[12] Bines J，Earl H，Buzaid AC，et al. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer：does the sequence matter? [J]. Ann Oncol，2014，25（6）：1079-1085.
[13] Kim HS，Lee SY，Kim JW，et al. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea [J]. Oncology，2016，91（5）：274-282.
[14] Kuderer NM，Dale DC，Crawford J，et al. Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy：A Systematic Review [J]. J Clin Oncol，2007，25（21）：3158-3167.
[15] Aapro M，Boccia R，Leonard R，et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer [J]. Support Care Cancer，2017，25（11）：3295-3304.
[16] Huang W，Liu J，Zeng Y，et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer [J]. Cancer Chemother Pharmacol，2018，82（4）：607-613.
[17] Puertolas I，Frutos Perez-Surio A，Alcacera MA，et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer [J]. Eur J Clin Pharmacol，2018，74（3）：315-321.
[18] Pawloski PA，Larsen M，Thoresen A，et al. Pegfilgrastim use and bone pain：a cohort study of community-based cancer patients [J]. J Oncol Pharm Pract，2016，22（3）：423-429.
[19] Group TW. The World Health Organization quality of life assessment（WHOQOL）：Development and general psychometric properties [J]. Soc Sci Med，1998，46（12）：1569-1585.
[20] Akel R，El Darsa H，Anouti B，et al. Anxiety，Depression and Quality of Life in Breast Cancer Patients in the Levant [J]. Asian Pac J Cancer Prev，2017，18（10）：2809-2816. |
|
|
|
